Company news

Oncolytics Biotech Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Oncolytics Biotech® Reports 2020 First Quarter Financial Results and Operational Highlights

May 8, 2020

Oncolytics Biotech® to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors at the ESMO Breast Cancer Virtual Meeting

May 4, 2020

Oncolytics Biotech® Announces Changes to Annual General Meeting

April 30, 2020

Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic

April 17, 2020

Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer

April 2, 2020

Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update

March 24, 2020

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

March 5, 2020

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

February 28, 2020

Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma

January 13, 2020

Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma

January 9, 2020

Oncolytics Biotech(R) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium

December 12, 2019

Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of Hematology

December 9, 2019

Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement

December 6, 2019

Oncolytics Biotech(R) Presents Clinical Data at the Fifth Annual Oncolytic Virotherapy Conference Highlighting Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue

December 3, 2019

Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights

November 12, 2019

Oncolytics Biotech(R) Announces Exercise of Warrants

November 12, 2019

Oncolytics Biotech(R) Announces AWARE-1 Data Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

November 8, 2019

Oncolytics Biotech(R) Announces Abstract Published for the 61st Annual Meeting & Exposition of the American Society of Hematology

November 6, 2019

Oncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma

November 6, 2019

Oncolytics Biotech(R) Provides Update on Partner Adlai Nortye's Clinical Progress

October 31, 2019

Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer

October 22, 2019

Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors

October 17, 2019

Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors

October 15, 2019

Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

October 1, 2019

Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta

September 30, 2019

Oncolytics Biotech(R) Announces Upcoming Presentation at the 12th Annual International Oncolytics Virus Conference

September 25, 2019

Oncolytics Biotech(R) Announces Upcoming Conference Participation

September 23, 2019

Oncolytics Biotech(R) Receives Nasdaq Notification Letter

September 20, 2019

Oncolytics Biotech(R) to Present at the Ladenburg Thalmann Healthcare Conference

September 17, 2019

Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference

September 5, 2019

Oncolytics Biotech(R) to Host Corporate Update Call to Discuss Recent Highlights and Expanded Catalysts and Milestones

September 4, 2019

Oncolytics Biotech(R) Announces Closing of Its Public Offering of Common Shares and Warrants

August 16, 2019

CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants

August 14, 2019

Oncolytics Biotech(R) Announces Pricing of Its Public Offering of Common Share and Warrants

August 14, 2019

Oncolytics Biotech(R) Announces Preliminary AWARE-1 Trial Data Demonstrating Viral Replication and Promotion of Inflammation Following Systemic Administration of Pelareorep When Combined with Tecentriq(R)

July 23, 2019

Oncolytics Biotech (R) to Host Conference Call to Discuss Co-Development Agreement with Pfizer and Merck KGaA

June 5, 2019

Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer

June 5, 2019

Oncolytics Biotech(R) to Present at the 9th Annual LD Micro Invitational Investor Conference

May 29, 2019

Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting

May 16, 2019

Oncolytics Biotech (R) Reports 2019 First Quarter Financial Results and Operational Highlights

May 3, 2019

Oncolytics Biotech(R) Announces Voting Results from the Annual General Meeting of Shareholders

May 3, 2019

Oncolytics Biotech(R) to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

April 23, 2019

Oncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer

April 8, 2019

Oncolytics Biotech(R) to Host Key Opinion Leader Meeting on the Emerging Role of Biomarkers and Oncolytic Viruses in the Treatment of Cancer

April 4, 2019

Oncolytics Biotech(R) to Present at the 18th Annual Needham Healthcare Conference

April 3, 2019

Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019

April 2, 2019

Oncolytics Biotech (R) Announces a Publication Highlighting Synergistic Effect of Pelareorep with a Proteasome Inhibitor in Preclinical Models of Multiple Myeloma

March 28, 2019

Oncolytics Biotech (R) Announces 2018 Year-End Results and Operational Highlights

March 8, 2019

Oncolytics Biotech(R) to Host Conference Call to Discuss Year End Financial Results and Operational Highlights

March 1, 2019

Oncolytics Biotech(R) Presents Biomarker Data in Second-line Pancreatic Cancer at AACR

February 27, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.